Aptamer Group Increases Revenue and Extends Funding Runway as Optimer Partnerships Expand

Aptamer Group (LSE:APTA) reported interim revenue of £0.83 million for the six months ended 31 December 2025, representing a 27% increase compared with the same period a year earlier. The company also reduced its adjusted EBITDA loss to £1.0 million and finished the period with £1.5 million in cash, supported by a £1.8 million fundraising completed in July 2025.

The group has since launched an Accelerated Book Build aimed at raising at least £3.75 million. If completed as planned, the funding is expected to extend Aptamer’s cash runway to 2028 and support continued asset development as well as the expansion of its AI-driven service capabilities.

Operationally, Aptamer progressed several key initiatives tied to its Optimer platform. During the period, it out-licensed enzyme-modulating Optimers to Twist Bioscience and Alphazyme, increased its manufacturing capacity and continued development of a delivery vehicle targeting fibrotic liver disease that has demonstrated favourable safety results in preclinical studies.

The company also strengthened commercial relationships with pharmaceutical and industrial partners through new and repeat fee-for-service agreements. These included its first major radioligand therapy collaboration and an expanded programme with Unilever. Aptamer believes these partnerships will help drive future product-linked income and royalty streams linked to the Optimer technology.

Despite these developments, the company’s outlook remains affected by financial challenges, including continued losses and negative cash flow. Technical indicators also remain weak, with the share price trading below major moving averages and showing negative MACD signals. While oversold momentum readings offer limited support, valuation remains constrained by negative earnings and the absence of dividend yield data.

More about Aptamer Group Plc

Aptamer Group plc is an AIM-listed biotechnology company developing synthetic binding molecules known as Optimers for applications in diagnostics, therapeutics and life science research tools. The company’s business model combines fee-for-service discovery programmes with internal asset development and licensing partnerships with global pharmaceutical, diagnostic and consumer goods companies.